{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T14:03:52Z","timestamp":1751637832620,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s00228-020-03004-w","type":"journal-article","created":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T05:02:36Z","timestamp":1600837356000},"page":"223-231","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7677-5927","authenticated-orcid":false,"given":"Allison","family":"Gaudy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Atsriku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"MacGorman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongjun","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sekhar","family":"Surapaneni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Palmisano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,23]]},"reference":[{"issue":"2","key":"3004_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","volume":"61","author":"ME Matyskiela","year":"2018","unstructured":"Matyskiela ME, Zhang W, Man HW, Muller G, Khambatta G, Baculi F, Hickman M, LeBrun L, Pagarigan B, Carmel G, Lu CC, Lu G, Riley M, Satoh Y, Schafer P, Daniel TO, Carmichael J, Cathers BE, Chamberlain PP (2018) A cereblon modulator (CC-220) with improved degradation of Ikaros and Aiolos. J Med Chem 61(2):535\u2013542","journal-title":"J Med Chem"},{"issue":"9","key":"3004_CR2","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nsmb.2874","volume":"21","author":"PP Chamberlain","year":"2014","unstructured":"Chamberlain PP, Lopez-Girona A, Miller K, Carmel G, Pagarigan B, Chie-Leon B, Rychak E, Corral LG, Ren YJ, Wang M, Riley M, Delker SL, Ito T, Ando H, Mori T, Hirano Y, Handa H, Hakoshima T, Daniel TO, Cathers BE (2014) Structure of the human cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat Struct Mol Biol 21(9):803\u2013809","journal-title":"Nat Struct Mol Biol"},{"issue":"6","key":"3004_CR3","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/bjh.12708","volume":"164","author":"AK Gandhi","year":"2014","unstructured":"Gandhi AK, Kang J, Havens CG, Conklin T, Ning Y, Wu L, Ito T, Ando H, Waldman MF, Thakurta A, Klippel A, Handa H, Daniel TO, Schafer PH, Chopra R (2014) Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br J Haematol 164(6):811\u2013821","journal-title":"Br J Haematol"},{"issue":"6168","key":"3004_CR4","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"G Lu","year":"2014","unstructured":"Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, Wong KK, Bradner JE, Kaelin WG (2014) The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343(6168):305\u2013309","journal-title":"Science"},{"key":"3004_CR5","doi-asserted-by":"crossref","unstructured":"Lonial S, v.d.D.N., Popat R, et al First clinical (phase 1b\/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM) ASCO, 2019. #8006","DOI":"10.1200\/JCO.2019.37.15_suppl.8006"},{"issue":"Supplement 1","key":"3004_CR6","first-page":"S22","volume":"97","author":"M Thomas","year":"2015","unstructured":"Thomas M, Y. Y, Weiss D et al (2015) Evaluation of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple oral doses of CC-220 in healthy subjects. Clin Pharmacol Ther 97(Supplement 1):S22","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"3004_CR7","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0928-0987(01)00135-X","volume":"13","author":"EL LeCluyse","year":"2001","unstructured":"LeCluyse EL (2001) Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 13(4):343\u2013368","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"3004_CR8","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1124\/dmd.31.4.421","volume":"31","author":"A Madan","year":"2003","unstructured":"Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeneira MD, Gan LS, LeCluyse EL, Zech K, Robertson P Jr, Koch P, Antonian L, Wagner G, Yu L, Parkinson A (2003) Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 31(4):421\u2013431","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"3004_CR9","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1124\/dmd.31.7.815","volume":"31","author":"TD Bjornsson","year":"2003","unstructured":"Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31(7):815\u2013832","journal-title":"Drug Metab Dispos"},{"key":"3004_CR10","unstructured":"FDA (2006) Draft Guidance for Industry. https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm292362.pdf"},{"issue":"5","key":"3004_CR11","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/clpt.2014.41","volume":"95","author":"AB Ke","year":"2014","unstructured":"Ke AB, Zamek-Gliszczynski MJ, Higgins JW, Hall SD (2014) Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies. Clin Pharmacol Ther 95(5):473\u2013476","journal-title":"Clin Pharmacol Ther"},{"key":"3004_CR12","unstructured":"Furie R, W. V, Gaudy A et al (2017) A randomized, placebo-controlled, double-blind, ascending-dose, safety, and pharmacokinetics study of CC-220 in subjects with systemic lupus erythematosus [abstract]. Arthritis Rheumatol 69(suppl 10)"},{"key":"3004_CR13","doi-asserted-by":"crossref","unstructured":"Lonial S, A. M, Popat R et al (2019) Translational and Clinical evidence of a differentiated profile for the novel CELMoD, iberdomide (CC-220). Blood 134(Supplement_1)","DOI":"10.1182\/blood-2019-124298"},{"key":"3004_CR14","first-page":"858","volume":"76","author":"A Gaudy","year":"2017","unstructured":"Gaudy A, Y Y, Korish S et al (2017) SAT0225 Cereblon modulator CC-220 decreases na\u00efve and memory B cells and plasmacytoid dendritic cells in systemic lupus erythematosus (SLE) patients: exposure-response results from a phase 2A proof of concept study. Ann Rheum Dis 76:858\u2013859","journal-title":"Ann Rheum Dis"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-03004-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-020-03004-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-03004-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:52:52Z","timestamp":1632358372000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-020-03004-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,23]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["3004"],"URL":"https:\/\/doi.org\/10.1007\/s00228-020-03004-w","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2020,9,23]]},"assertion":[{"value":"5 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Allison Gaudy, Ying Ye, Kimberly MacGorman, Christian Atsriku, Liangang Liu, Yongjun Xue, Sekhar Surapaneni and Maria Palmisano are all full-time employees of Bristol Myers Squibb, and own stock in the company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}